Evidence map›Paper›PMID 28125838›Full record

ArticleInvestigative ophthalmology & visual science2017

The Pattern of Retinal Ganglion Cell Loss in OPA1-Related Autosomal Dominant Optic Atrophy Inferred From Temporal, Spatial, and Chromatic Sensitivity Losses.

Anna Majander, Catarina João, Andrew T Rider, G Bruce Henning, Marcela Votruba, Anthony T Moore, Patrick Yu-Wai-Man, Andrew Stockman

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. PathogenicBrain communications · 2021
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Anna MajanderUniversity College London, Institute of Ophthalmology, London, United Kingdom 2Moorfields Eye Hospital, London, United Kingdom 3Department of Ophthalmology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.
Catarina JoãoUniversity College London, Institute of Ophthalmology, London, United Kingdom.
Andrew T RiderUniversity College London, Institute of Ophthalmology, London, United Kingdom.
G Bruce HenningUniversity College London, Institute of Ophthalmology, London, United Kingdom.
Marcela VotrubaSchool of Optometry and Vision Sciences, Cardiff University Cardiff, and Cardiff Eye Unit, University Hospital Wales, Cardiff, United Kingdom.
Anthony T MooreUniversity College London, Institute of Ophthalmology, London, United Kingdom 2Moorfields Eye Hospital, London, United Kingdom 5Ophthalmology Department, University of California-San Francisco School of Medicine, San Francisco, California, United States.
Patrick Yu-Wai-ManUniversity College London, Institute of Ophthalmology, London, United Kingdom 2Moorfields Eye Hospital, London, United Kingdom 6Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University and Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
Andrew StockmanUniversity College London, Institute of Ophthalmology, London, United Kingdom.
University College London · GBMoorfields Eye Hospital · GBUniversity Hospital of Wales · GBWellcome Centre for Mitochondrial Research · GB

Funding

Biotechnology and Biological Sciences Research CouncilDepartment of HealthMedical Research Council G0701386Medical Research Council G1002570
6 · The paper itself

Abstract

Purpose: Progressive retinal ganglion cell (RGC) loss is the pathological hallmark of autosomal dominant optic atrophy (DOA) caused by pathogenic OPA1 mutations. The aim of this study was to conduct an in-depth psychophysical study of the visual losses in DOA and to infer any selective vulnerability of visual pathways subserved by different RGC subtypes. Methods: We recruited 25 patients carrying pathogenic OPA1 mutations and age-matched healthy individuals. Spatial contrast sensitivity functions (SCSFs) and chromatic contrast sensitivity were quantified, the latter using the Cambridge Colour Test. In 11 patients, long (L) and short (S) wavelength-sensitive cone temporal acuities were measured as a function of target illuminance, and L-cone temporal contrast sensitivity (TCSF) as a function of temporal frequency. Results: Spatial contrast sensitivity functions were abnormal, with the loss of sensitivity increasing with spatial frequency. Further, the highest L-cone temporal acuity fell on average by 10 Hz and the TCSFs by 0.66 log10 unit. Chromatic thresholds along the protan, deutan, and tritan axes were 8, 9, and 14 times higher than normal, respectively, with losses increasing with age and S-cone temporal acuity showing the most significant age-related decline. Conclusions: Losses of midget parvocellular, parasol magnocellular, and bistratified koniocellular RGCs could account for the losses of high spatial frequency sensitivity and protan and deutan sensitivities, high temporal frequency sensitivity, and S-cone temporal and tritan sensitivities, respectively. The S-cone-related losses showed a significant deterioration with increasing patient age and could therefore prove useful biomarkers of disease progression in DOA.

Indexed as

MutationAdolescentAdultAgedColor PerceptionContrast SensitivityDisease ProgressionDNADNA Mutational AnalysisFemaleFlicker FusionGTP PhosphohydrolasesHumansMaleMiddle AgedOptic Atrophy, Autosomal DominantDNAGTP PhosphohydrolasesOPA1 protein, human

Identifiers

PMID28125838
PMCPMC5283089
OpenAlexW2580808497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.